Pharma-biotech collaborations: Eight themes from Biocom's Partnering Conference
This article was originally published in Scrip
Big pharma, small biotech and academic institutions are experimenting with new ways of working together, and San Diego's life science industry group Biocom invited deal makers to town on 26 and 27 February to share their ideas.
You may also be interested in...
Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.
Recent financings, including the $150m launch of Pathalys and a planned $100m IPO for Mineralys, illustrate the reality of biopharma funding in 2023 – that having near-term clinical trial milestones are key to fundraising this year. Companies with dwindling cash are conserving the funds they have left.
Lilly plans to seek traditional approval for its amyloid-clearing antibody after the Phase III TRAILBLAZER-ALZ 2 trial reads out in Q2, but it loses important ground in reimbursement negotiations.